A perspective on protein profiling of blood

BJU International

Volumn 96, Issue 4, 2005, Pages 477-482

  Katz, Jonathan E ^a   Mallick, Parag ^a   Agus, David B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Mass spectrometry; Plasma; Profiling; Proteomics; Serum

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

BLADDER RECONSTRUCTION; BLOOD CHEMISTRY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INFRARED SPECTROSCOPY; KIDNEY CANCER; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; MICROSATELLITE INSTABILITY; ONCOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEOMICS; SHORT SURVEY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UROLOGY;

BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; HUMANS; MALE; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 24144502955     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05669.x     Document Type: Short Survey

References (47)

1. Hofler H, Specht K, Becker KF. Molecular analysis of gene expression in tumor pathology. Adv Exp Med Biol 2003; 532: 19-26
2. Cordon-Cardo C, Koff A, Drobnjak M et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998; 90: 1284-91
3. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720-30
4. Chen G, Gharib TG, Huang CC et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1: 304-13
5. Hanash SM, Baier LJ. Two-dimensional gel electrophoresis of cellular proteins reveals myeloid origin of blasts in two children with otherwise undifferentiated leukemia. Cancer 1986; 57: 1539-43
6. Wirth PJ, Egilsson V, Gudnason V, Ingvarsson S, Thorgeirsson SS. Specific polypeptide differences in normal versus malignant human breast tissues by two-dimensional electrophoresis. Breast Cancer Res Treat 1987; 10: 177-89
7. Stein RC, Zvelebil MJ. The application of 2D gel-based proteomics methods to the study of breast cancer. J Mammary Gland Biol Neoplasia 2002; 7: 385-93
8. Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 2000; 97: 9390-5
9. Zuo X, Hembach P, Echan L, Speicher DW. Enhanced analysis of human breast cancer proteomes using micro-scale solution isoelectrofocusing combined with high resolution 1-D and 2-D gels. J Chromatogr B Anal Technol Biomed Life Sci 2002; 782: 253-65
10. Zuo X, Speicher DW. A method for global analysis of complex proteomes using sample prefractionation by solution isoelectrofocusing prior to two-dimensional electrophoresis. Anal Biochem 2000; 284: 266-78
11. Patton WF. Detection technologies in proteome analysis. J Chromatogr B Anal Technol Biomed Life Sci 2002; 771: 3-31
12. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. Mol Cell Proteomics 2004;
13. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246: 64-71
14. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988; 60: 2299-301
15. Stafford GC, Kelley PE, Syka JEP, Reynolds WE, Todd JF. Recent improvements in and analytical applications of advanced ion-trap technology. Int J Mass Spectrometry Ion Processes 1984; 60: 85-98
16. Marshall AG, Hendrickson CL, Jackson GS. Fourier transform ion cyclotron resonance mass spectrometry: a primer. Mass Spectrom Rev 1998; 17: 1-35
17. Boyanton BL, Blick, KE. Stability studies of twenty-four analytes in human plasma and serum. Clin Chem 2002; 48: 2242-7
18. Ellis MJ, Livesey JH, Evans MJ. Hormone stability in human whole blood. Clin Biochem 2003; 36: 109-12
19. Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001; 34: 107-12
20. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002; 2: 311-5
21. Spence GM, Graham AN, Mulholland K et al. Vascular endothelial growth factor levels in serum and plasma following esophageal cancer resection - relationship to platelet count. Int J Biol Markers 2002; 17: 119-24
22. Bauernhofer T, Zenahlik S, Hofmann G et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncol Report 2005; 13: 179-84
23. Sher YP, Shih JY, Yang PC et al. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res 2005; 11: 173-9
24. Anderson NL, Anderson NG. The human plasma proteome. history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-67
25. McDonald WH, Yates JR. Shotgun proteomics and biomarker discovery. Dis Markers 2002; 18: 99-105
26. Yan JX, Devenish AT, Wait R, Stone T, Lewis S, Fowler S. Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of Escherichia coli. Proteomics 2002; 2: 1682-98
27. Alban A, David SO, Bjorkesten L et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003; 3: 36-44
28. Bjorhall K, Miliotis T, Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2004; 5: 307-17
29. Kalume DE, Molina H, Pandey A. Tackling the phosphoproteome. Tools and strategies. Curr Opin Chem Biol 2003; 7: 64-9
30. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003; 21: 255-61
31. Zhang H, Yi EC, Li XJ et al. High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. Mol Cell Proteomics 2004;
32. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003; 21: 660-6
33. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7
34. Petricoin EF, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-8
35. Check E. Proteomics and cancer: running before we can walk? Nature 2004; 429: 36.
36. Grizzle WE, Adam BL, Bigbee WL et al. Serum protein expression profiling for cancer detection, validation of a SELDI-based approach for prostate cancer. Dis Markers 2003; 19: 185-95
37. Semmes OJ, Feng Z, Adam BL et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer. I. Assessment of platform reproducibility. Clin Chem 2005; 51: 102-12
38. He F, Hendrickson CL, Marshall AG. Baseline mass resolution of peptide isobars: a record for molecular mass resolution. Anal Chem 2001; 73: 647-50
39. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7
40. George DJ, Kantoff PW. Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 1999; 26: 303-10
41. Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NJ. A prognostic score for hormone-refractory prostate cancer, analysis of two cancer and leukemia group B studies. Clin Cancer Res 1999; 5: 831-7
42. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-82
43. Hendrickson CL, Emmett MR. Electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Annu Rev Phys Chem 1999; 50: 517-36
44. Ball G, Mian S, Holding F, Allibone RO et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 2002; 18: 395-404
45. Qu Y, Adam BL, Yasui Y et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835-43
46. Fung ET, Enderwick C. ProteinChip clinical proteomics. computational challenges and solutions. Biotechniques Suppl, 2002; 34-38: 40-31
47. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-304